BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference [Yahoo! Finance]
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: Yahoo! Finance
90–98% suppression of IL-1ß and a substantial proportion of participants in the 120 mg obese cohort reaching hs-CRP below 1 mg/L BioAge plans mid-year proof-of-concept trials: a three-dose, three-month cardiovascular risk study with year-end data expected, and an 8-week DME study (~30 patients per arm) assessing intraocular IL-6 with anti-VEGF combination and monotherapy arms. Financially, the company ended last year with $285 million in cash, raised about $125 million net in Q1, and forecasts a budget supporting **more than three years** of cash runway while advancing two APJ agonist obesity programs with a first IND planned by year-end. Interested in BioAge Labs, Inc.? Here are five stocks we like better. BioAge Labs (NASDAQ:BIOA) used a presentation at the 25th Annual Needham Virtual Healthcare Conference to outline near-term clinical catalysts for its lead NLRP3 inflammasome inhibitor and provide updates on additional pipeline programs and its cash position. Chief Financ
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioArctic publishes the Annual Report and Sustainability Report for 2025PR Newswire
- BioArctic publishes the Annual Report and Sustainability Report for 2025PR Newswire
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP [Yahoo! Finance]Yahoo! Finance
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPGlobeNewswire
- BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year [Seeking Alpha]Seeking Alpha
BIOA
Earnings
- 3/24/26 - Miss
BIOA
Sec Filings
- 4/21/26 - Form DEFA14A
- 4/21/26 - Form DEF
- 4/3/26 - Form 4
- BIOA's page on the SEC website